We are live on ! Find out more
CNTB icon

Connect Biopharma Holdings

0.5900 USD
-0.0382
6.08%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
0.5800
-0.0100
1.69%
1 day
-6.08%
5 days
-12.54%
1 month
-32.59%
3 months
-74.12%
6 months
-74.46%
Year to date
-76.59%
1 year
-81.27%
5 years
-87.42%
10 years
-96.81%
 

About: Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Employees: 64

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 16.7%
Neutral 66.7%
Negative 16.7%
Neutral
GlobeNewsWire
5 days ago
Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
– Reported positive preliminary topline data from global Phase 2 Seabreeze STAT studies evaluating rademikibart as an adjunct treatment for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) –
Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
Neutral
Seeking Alpha
29 days ago
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Positive
Zacks Investment Research
1 month ago
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
Neutral
Zacks Investment Research
1 month ago
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
Negative
MarketBeat
1 month ago
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reductions in treatment failures during the month after an exacerbation.
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
Positive
Benzinga
1 month ago
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Neutral
Seeking Alpha
1 month ago
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
Neutral
Seeking Alpha
2 months ago
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Negative
Benzinga
2 months ago
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasing topline results from its global Phase 2 study evaluating rademikibart.
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Price charts implemented using Lightweight Charts™